The situation at packaging specialist Gerresheimer has deteriorated sharply, with a recent regulatory announcement fueling investor alarm instead of providing clarity. Germany’s Federal Financial Supervisory Authority, BaFin, has significantly expanded its investigation into the company’s accounting practices, now including the current fiscal year. This move dashes hopes for a swift resolution, pushing the publication of reliable financial figures far into the future.
Stock Price Reflects Mounting Uncertainty
The market has reacted severely to the prolonged uncertainty. Over a twelve-month period, the share price has recorded a staggering loss of approximately 80 percent. While the stock traded slightly higher at €15.85 in recent activity, this minor gain is viewed as a technical rebound within a persistent downtrend, especially following yesterday’s 52-week low of €15.57. The company remains fundamentally difficult to value while the audit is ongoing and the annual report is indefinitely postponed. The true substance of the business will only become clear once the full scope of necessary balance sheet corrections is transparently disclosed.
Broadened Investigation Scrutinizes Multiple Areas
BaFin’s widened inquiry places specific balance sheet items from fiscal 2023/2024 under intense scrutiny. The regulator is examining potential errors related to lease liabilities and capitalized development costs. A particularly critical focus is on the Swiss subsidiary, Sensile Medical. Investigators are probing whether necessary impairment charges on assets worth nearly €200 million were incorrectly omitted. The company had previously indicated it would book non-cash depreciations of a similar magnitude for the 2025 consolidated financial statements.
Should investors sell immediately? Or is it worth buying Gerresheimer?
The authority’s review is not limited to past periods. It now also encompasses the timeframe from December 1, 2024, through the end of May 2025. This part of the investigation centers on so-called “bill-and-hold” transactions. A serious suspicion underlies this examination: were revenues recorded in the books for goods that had not yet left the warehouse? The associated valuation of inventory linked to these transactions is also being questioned.
Legal Repercussions Loom for Former Executives
Operational leadership has already been overhauled, with former CEO Dietmar Siemssen and ex-CFO Bernd Metzner having departed the company. Now, legal challenges from investors are emerging. The Deutsche Schutzvereinigung für Wertpapierbesitz (DSW), a German shareholder association, is mobilizing investors and evaluating potential damage claims against former members of the executive board. An expert report assessing liability is already in preparation.
The extended audit timeline means reliable financial data remains elusive. Investors hoping for a quick clarification now face a prolonged period of uncertainty as the company works through the regulatory process and necessary financial restatements.
Ad
Gerresheimer Stock: Buy or Sell?! New Gerresheimer Analysis from February 28 delivers the answer:
The latest Gerresheimer figures speak for themselves: Urgent action needed for Gerresheimer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 28.
Gerresheimer: Buy or sell? Read more here...









